The New England journal of medicine, 2020-05, Vol.382 (20), p.1883-1893
2020
Details
- Autor(en) / Beteiligte
- Titel
- Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
- Ist Teil von
- The New England journal of medicine, 2020-05, Vol.382 (20), p.1883-1893
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Link zum Volltext
- Quelle
- Alma/SFX Local Collection
- Beschreibungen/Notizen
- Patients with chronic heart failure and a reduced ejection fraction were randomly assigned to the soluble guanylate cyclase stimulator vericiguat or placebo, in addition to guideline-based medical therapy. The incidence of death from cardiovascular causes or first hospitalization for heart failure was lower among patients who received vericiguat.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793, 1533-4406eISSN: 1533-4406DOI: 10.1056/NEJMoa1915928Titel-ID: cdi_swepub_primary_oai_DiVA_org_uu_430620
- Format
- –
- Schlagworte
- Administration, Oral, Aged, Binding sites, Blood pressure, Cardiac output, Cardiology and cardiovascular system, Cardiovascular Diseases - mortality, Chronic Disease, Congestive heart failure, Control, Death, Diuretics, Double-Blind Method, Drug therapy, Ejection fraction, Enrollments, Female, Follow-Up Studies, Guanylate cyclase, Heart failure, Heart Failure - drug therapy, Heart Failure - physiopathology, Heterocyclic Compounds, 2-Ring - adverse effects, Heterocyclic Compounds, 2-Ring - therapeutic use, Hospitalization, Hospitalization - statistics & numerical data, Human health and pathology, Humans, Hypotension, Hypotension - chemically induced, Incidence, Intravenous administration, Life Sciences, Male, Middle Aged, Patient outcomes, Patient safety, Peptides, Pyrimidines - adverse effects, Pyrimidines - therapeutic use, Soluble Guanylyl Cyclase - metabolism, Stroke Volume, Syncope, Syncope - chemically induced, Testing, Ventricular Dysfunction, Left - drug therapy